DOCSLIB.ORG

Syntheses and Biological Activity of Sparsomycin and Analogs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Syntheses and Biological Activity of Sparsomycin and Analogs SYNTHESES AND BIOLOGICAL ACTIVITY OF SPARSOMYCIN AND ANALOGS THE CHEMISTRY OF CHIRAL FUNCTIONALIZED SULFOXIDES AND SULTINES DERIVED FROM CYSTEINE ROB M.J. LISKAMP SYNTHESES AND BIOLOGICAL ACTIVITY OF SPARSOMYCIN AND ANALOGS THE CHEMISTRY OF CHIRAL FUNCTIONALIZED SULFOXIDES AND SULTINES DERIVED FROM CYSTEINE Promotor : Prof. Dr. R.J.F. Nivard Co-referent : Dr. H.C.J. Ottenheijm SYNTHESES AND BIOLOGICAL ACTIVITY OF SPARSOMYCIN AND ANALOGS THE CHEMISTRY OF CHIRAL FUNCTIONALIZED SULFOXIDES AND SULTINES DERIVED FROM CYSTEINE PROEFSCHRIFT TER VERKRIJGING VAN DE GRAAD VAN DOCTOR IN DE WISKUNDE EN NATUURWETENSCHAPPEN AAN DE KATHOLIEKE UNIVERSITEIT VAN NIJMEGEN OP GEZAG VAN DE RECTOR MAGNIFICUS PROF. DR. J.H.G.I. GIESBERS VOLGENS HET BESLUIT VAN HET COLLEGE VAN DEKANEN IN HET OPENBAAR TE VERDEDIGEN OP VRIJDAG 10 DECEMBER 1982 DES NAMIDDAGS OM 4 UUR DOOR ROBERTUS MATTHIAS JOSEPH LISKAMP GEBOREN TE NIJMEGEN NIJMEGEN 1982 Dit proefschrift vormt de neerslag van vier jaar wetenschappelijk onderzoek. Ik wil iedereen - en dat waren er zeer velen - bedanken, die hieraan gedurende die tijd door hun stimulerende discussie of door de feitelijke uitvoering deel hadden. Zij gaven mede richting en vorm, niet alleen organisch maar ook biochemisch/biologisch en fysisch chemisch, aan het verrichte onderzoek. Daarnaast wil ik hen bedanken die een bijdrage geleverd hebben aan de onmis­ bare technische uitvoering van het in dit proefschrift beschreven onderzoek. En tenslotte wil ik ook hen bedanken die aan de vormgeving van het proef­ schrift hun medewerking hebben verleend. Tekeningen : Wim van Luijn en de afdeling illustratie Type-werk : Dorine Hesselink-Balvert Afbeelding op de omslag: Een 'stacked plot' van een 2D-spin-echo correlated spectrum van synthetisch sparsomycine verzorgd door Wim Guijt This research was supported by the Netherlands Foundation for Chemical Research (SON) with financial aid from the Netherlands Organization for the Advancement of Pure Research (ZWO). Het leven is een pijpkaneel CONTENTS CHAPTER I General intractuation. 1 Introduction to the Chapters. 7 CHAPTER II 9 Absolute Configuration of Sparsomyoin. A Chiroptical Study of Sulfoxides. H.C.J. Ottenheijm, R.M.J. Liskamp, P. Helquist, J.W. Lauher, M.S. Shekhani, J. Am. Chem. Soo. (1981), 103, 1720. CHAPTER III 13 Total Synthesis of the Antibiotic Sparsomycinj a Modified Uracil Amino Add Mono-oxodithioacetal. H.C.J. Ottenheijm, R.M.J. Liskamp, S.P.J.M. van Nispen, H.A. Boots, M.W. Tijhuis, J. Org. Chem. (1981), 46, 3273. CHAPTER IV 24 Synthesis and Ring-Opening Reactions of Functionalized Sultines. A new Approach to Sparsomyein. R.M.J. Liskamp, H.J.M. Zeegers, H.C.J. Ottenheijm, J. Org. Chem. (1981), 46, 5408. CHAPTER V 1. Interactions of sparsomyoin with the peptidyttransferase 30 center of ribosomes 2. Inhibition of the 'protein' synthesis in yeast 38 (Saccharomyces Cerevisae) cell-free systems by sparsomyoin and analogs; preliminary results of a structure-activity relationship study. 3. Structure-Activity Relationships of Sparsomyoin and 40 Analogs; Octylsparsomycin: the First Analog More Active than Sparsomyoin R.M.J. Liskamp, J.H. Colstee, H.C.J. Ottenheijm, P. Lelieveld, W. Akkerman, J. Med. Chem. submitted for publication 4. The antitumor activity of sparsomyoin 53 CHAPTER VI 56 Conformational Analysis of Funotionalized SulbLnes by Nuclear Magnetic Resonance and X-Ray Crystallography ; Application of a Generalized Karplus equation. C.A.G. Haasnoot, R.M.J. Liskamp, P.A.W. van Dael, J.H. Noordik, H.C.J. Ottenheijm, J. Am. Chem. Soc., submitted for publication. CHAPTER VII 76 Flash Vacuum Thermolysis of Funotionalized y-Sultines R.M.J. Liskamp, H.J.M. Blom, R.J.F. Nivard, H.C.J. Ottenheijm, J. Org. Chem., submitted for publication. CHAPTER VIII 84 Approaches to the marasmin fragment of y-glutamylmarasmin SAMENVATTING 97 CURRICULUM VITAE 101 CHAPTER I GENERAL INTRODUCTION INTRODUCTION TO THE CHAPTERS GENERAL INTRODUCTION The isolation of sparsomycin 1^, next to tubericidin (sparsomycin A) 21, from a Streptomyoes Sparsogenes broth was reported by Argoudelis and Herr in 19622'3. More recently this compound has also been obtained from Stvevtomyaes Cuspidosporus1* »5. After its isolation it was roughly characterized (UV, IR, elementary analysis, specific rotation and molecular weight) by Argoudelis and Herr . ОН о "H2 Us. ΐ ON OH 1 Sparsomycin (Sc- Rs) 2 tubericidin Subsequently a first evaluation of its biological activity was carried out by Owen, Dietz and Camiener6. In their experiments sparsomycin was found to be active against KB human epidermoid carcinoma cells in tissue culture. The compound was very active against these mammalian cells (KB cell protein synthesis was inhibited 50% (ID50) at a concentration of 0.05 pg/ml), and moderately active against a variety of gram negative and gram positive bacteria as well as against fungi. In VÌVO data showed inhibition of growth of several tumors as assayed from tumor diameter measurements or from tumor weights. The toxicological screening of sparsomycin indicated an acute LD50 value of 2.4 mg/kg in mice. These data about the biological activity were probably the immediate cause to test sparsomycin in a phase I clinical study in 19647. In this study with 5 patients who had all advanced carcinomas or sarcomas, the drug was daily administered i.V. for an intended period of 42 days. The dose given ranged from 0.085 mgAg - 0.24 mg/kg. Two patients noted difficulty of vision, one after 13 days of treatment (total dose 12 mg) and one after 15 days of treatment (total dose 7.5 mg), where­ after treatment was stopped. It was conceived, that the primary biological activity of sparsomycin was due to a strong inhibition of the protein synthesis rather than inhi­ bition of DNA or RNA synthesis. Its effect on the protein synthesis was demonstrated by the decline of the protein synthesis of intact prokaryotic cells Ч6/8-12, eukaryotic cells13"^0 - including transformed6'0'9'19'20 and/or virus infected cells » ; and in various cell-free systems (pro- karyotes13'23-26'34, eukaryotes27-41). The behavior of sparsomycin with regard to its inhibitory action and influence on the polyribosomes has also been investigated гп vivoi*2-~t*7. There is ample evidence4"»^9 that sparsomycin inhibits the protein synthesis by interacting with the peptidyltransferase center of ribosomes, the devices of the cell, where the protein synthesis actually takes place. The peptidyltransferase center is responsible for the cruxial event in the elongation step of the protein synthesis in which the peptidyl chain of the peptidyl-tRNA is transferred to the aminoacyl-tRNA. 2 The pronounced inhibition of the protein synthesis may be - at least partly - responsible for several reported secondary actions of sparsomycin, such as the inhibition of the RNA-synthesis13, the DNA-synthesis16 and perhaps also for the reported ocular toxicity of sparsomycin6»50. Because sparsomycin is a selective and effective inhibitor of the protein synthesis, it has been used as a tool in a number of other biochemical studies15»51~60. Our interest in sparsomycin was roused by the discrepancy that existed between the wealth of information on the biological activity as well as the biochemical mechanism of action (vide supra) on one hand and the limited knowledge of the organic chemistry of the molecule on the other hand: when we started our research on sparsomycin there was no total synthesis of the molecule available. To our opinion the development of a flexible synthesis or synthetic methodologies for a molecule possessing an interesting biological activity is an absolute prerequisite for thorough studies on the biological activity and/or biochemical mechanisms of interaction. This can also be concluded from the work on - especially - puromycin (Chapter V), on chloramphenicol and on lincomycin, which interfere with the peptidyltransferase center too. As a consequence we started our investigations on sparsomycin, directing our first efforts towards a total synthesis of this molecule. A total synthesis was feasible since the structure of sparsomycin - excepting the chirality of the sulfoxide moiety - had been elucidated by Wiley and MacKellar61 in 1970. Our purpose was to develop a flexible synthesis that would enable us to prepare a wide variety of analogs. It was planned to use these analogs in structure activity relationship studies (see Chapter V) to determine : a^ the structural features and stereochemical requirements, essential for an optimal biological activity b the molecular mechanism of action of sparsomycin and its analogs. In addition, our aim was to study whether structural modifications in sparsomycin might yield a molecule with more selective biochemical and farmacological properties e.g. a molecule that will penetrate preferentially into a transformed cell. Furthermore, our experiences with the syntheses of analogs of sparsomycin will be used to develop a synthesis of a sparsomycin analog, containing a radioactive label as well as an affinity label. The latter may give rise to covalent bond(s) with (a) molecule(s) of its site of interaction. Studies with this affinity analog of sparsomycin might be valuable for an further understanding of ribosome structure and function. The guiding principle in structure-activity relation studies and in affinity label studies has to be the awareness of the existence of a close relation between the structure as well as the chemistry of a molecule and its biological activity. This implies a 'bio-organic chemical' attitude: hypotheses have to be formulated based on results obtained from studies on the biological activity of an effector molecule and on available information about the biochemical/biological structure of the effector's target (e.g. the ribosome). These hypotheses must lead to the design of molecular models. Although the biological activity of sparsomycin was an important reason for directing our synthetic efforts toward this molecule, there were other reasons for embarkment on a total synthesis. First, the development of a total synthesis would allow the determination of the absolute configuration of the sulfoxide-sulfur atom of sparsomycin.
Load more

Recommended publications
  • The Ribosomal Peptidyl Transferase Center: Structure, Function, Evolution, Inhibition
    Critical Reviews in Biochemistry and Molecular Biology, 40:285–311, 2005 Copyright c Taylor & Francis Inc. ! ISSN: 1040-9238 print / 1549-7798 online DOI: 10.1080/10409230500326334 The Ribosomal Peptidyl Transferase Center: Structure, Function, Evolution, Inhibition Norbert Polacek Innsbruck Biocenter, Division of ABSTRACT The ribosomal peptidyl transferase center (PTC) resides in the Genomics and RNomics, large ribosomal subunit and catalyzes the two principal chemical reactions of Innsbruck Medical University, protein synthesis: peptide bond formation and peptide release. The catalytic Innsbruck, Austria mechanisms employed and their inhibition by antibiotics have been in the Alexander S. Mankin focus of molecular and structural biologists for decades. With the elucidation Center for Pharmaceutical of atomic structures of the large ribosomal subunit at the dawn of the new Biotechnology, University of millennium, these questions gained a new level of molecular significance. The Illinois at Chicago, Chicago, crystallographic structures compellingly confirmed that peptidyl transferase is IL 60607, USA an RNA enzyme. This places the ribosome on the list of naturally occurring riboyzmes that outlived the transition from the pre-biotic RNA World to con- temporary biology. Biochemical, genetic and structural evidence highlight the role of the ribosome as an entropic catalyst that accelerates peptide bond for- mation primarily by substrate positioning. At the same time, peptide release should more strongly depend on chemical catalysis likely involving an rRNA group of the PTC. The PTC is characterized by the most pronounced accu- mulation of universally conserved rRNA nucleotides in the entire ribosome. Thus, it came as a surprise that recent findings revealed an unexpected high level of variation in the mode of antibiotic binding to the PTC of ribosomes from different organisms.
    [Show full text]
  • Phytochem Referenzsubstanzen
    High pure reference substances Phytochem Hochreine Standardsubstanzen for research and quality für Forschung und management Referenzsubstanzen Qualitätssicherung Nummer Name Synonym CAS FW Formel Literatur 01.286. ABIETIC ACID Sylvic acid [514-10-3] 302.46 C20H30O2 01.030. L-ABRINE N-a-Methyl-L-tryptophan [526-31-8] 218.26 C12H14N2O2 Merck Index 11,5 01.031. (+)-ABSCISIC ACID [21293-29-8] 264.33 C15H20O4 Merck Index 11,6 01.032. (+/-)-ABSCISIC ACID ABA; Dormin [14375-45-2] 264.33 C15H20O4 Merck Index 11,6 01.002. ABSINTHIN Absinthiin, Absynthin [1362-42-1] 496,64 C30H40O6 Merck Index 12,8 01.033. ACACETIN 5,7-Dihydroxy-4'-methoxyflavone; Linarigenin [480-44-4] 284.28 C16H12O5 Merck Index 11,9 01.287. ACACETIN Apigenin-4´methylester [480-44-4] 284.28 C16H12O5 01.034. ACACETIN-7-NEOHESPERIDOSIDE Fortunellin [20633-93-6] 610.60 C28H32O14 01.035. ACACETIN-7-RUTINOSIDE Linarin [480-36-4] 592.57 C28H32O14 Merck Index 11,5376 01.036. 2-ACETAMIDO-2-DEOXY-1,3,4,6-TETRA-O- a-D-Glucosamine pentaacetate 389.37 C16H23NO10 ACETYL-a-D-GLUCOPYRANOSE 01.037. 2-ACETAMIDO-2-DEOXY-1,3,4,6-TETRA-O- b-D-Glucosamine pentaacetate [7772-79-4] 389.37 C16H23NO10 ACETYL-b-D-GLUCOPYRANOSE> 01.038. 2-ACETAMIDO-2-DEOXY-3,4,6-TRI-O-ACETYL- Acetochloro-a-D-glucosamine [3068-34-6] 365.77 C14H20ClNO8 a-D-GLUCOPYRANOSYLCHLORIDE - 1 - High pure reference substances Phytochem Hochreine Standardsubstanzen for research and quality für Forschung und management Referenzsubstanzen Qualitätssicherung Nummer Name Synonym CAS FW Formel Literatur 01.039.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0275279 A1 Rozzell Et Al
    US 20060275279A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0275279 A1 ROZZell et al. (43) Pub. Date: Dec. 7, 2006 (54) METHODS FOR DISSOLVING CYSTINE (22) Filed: Jun. 6, 2005 STONES AND REDUCING CYSTINE IN URINE Publication Classification (76) Inventors: J. David Rozzell, Burbank, CA (US); (51) Int. Cl. Kavitha Vedha-Peters, Pasadena, CA A6II 38MSI (2006.01) (US) (52) U.S. Cl. ............................................................ 424/94.5 Correspondence Address: CHRISTIE, PARKER & HALE, LLP (57) ABSTRACT PO BOX 7O68 PASADENA, CA 91109–7068 (US) The present invention is directed to an improved method of treating cystinuria, utilizing the catalytic ability of cystinase (21) Appl. No.: 11/146,551 to increase the rate of cystine Stone dissolution. Patent Application Publication Dec. 7, 2006 Sheet 1 of 4 US 2006/0275279 A1 Hs1N1 Ncoh L-Homocysteine -- H2 O HOC n1ns 1-1N CO2H Cystathionine?3-lyase ls CO2H H2 Pyruvate L-Cystathionine H NH FIG. 1. Metabolic Reaction Catalyzed by Cystathionine-?s-Lyase Patent Application Publication Dec. 7, 2006 Sheet 2 of 4 US 2006/0275279 A1 NH2 Hs1 S Y1Ncoh L-Thiocysteine -- NH2 O Hozen-1- 1N1 no H Cystathionine e i 2 B-lyase CO2H NH2 P L-CystineA- y ruvate -- NH FIG. 2. "Un-Natural" Reaction Catalyzed by Cystathionine-?s-Lyase on L-Cystine Patent Application Publication Dec. 7, 2006 Sheet 3 of 4 US 2006/0275279 A1 Dissolution of Cystine Stones with Cystathionine beta-lyase (MetC) s -o-control (no MetC) al -H 1 mg/mL MetC g - 5 mg/mL MetC 3. -- 10 mg/mL MetC S.
    [Show full text]
  • Sparsomycin and Its Analogues
    PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/113516 Please be advised that this information was generated on 2021-10-06 and may be subject to change. SPARSOMYCIN AND ITS ANALOGUES A preclinical study on novel anticancer drugs Promotores: Prof. Dr. D.J.Th. Wagener Prof. Dr. E. van der Kleijn Prof. Dr. H.C.J. Ottenheijm (V.U., Amsterdam) SPARSOMYCIN AND ITS ANALOGUES A preclinical study on novel anticancer drugs een wetenschappelijke proeve op het gebied van de geneeskunde en tandheelkunde PROEFSCHRIFT ter verkrijging van de graad van doctor aan de Katholieke Universiteit te Nijmegen, volgens besluit van het college van decanen in het openbaar te verdedigen op dinsdag 7 juni 1988 des namiddags te 3.30 uur door Zbigniew Zylicz geboren op 13 juni 1955 te Wroclaw (Polen) Nijmegen, 1988 druk: reprografie faculteit der geneeskunde en tandheelkunde The investigations have been performed at the Department of Internal Medicine, Division of Medical Oncology, and the Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands. These studies were supported by The Netherlands Cancer Foundation Queen Wilhelmina Fund (grant nr SNUKC-84-1) and Pharmachemie BV, Haarlem, The Netherlands. Pharmachemie BV, Haarlem, is also acknowledged for financial support of publication of this thesis. Yr3/V)ornm vr? тле/ г$и Abbreviat ions AUG - area under the plasma concentration versus time curve ARA-C - cytosine arabinoside CHO - Chinese hamster ovary cells CL-j, - creatinine clearance CL™ - non-renal clearance CLp - renal clearance С - steady state concentration D - dose dSm - deshydroxy-sparsomycin EdSm - ethyl-deshydroxy-sparsomycin 5-FU - 5-fluorouracil i.d.
    [Show full text]
  • Copyrighted Material
    Index Abhexon, 501, 565 bitter, 636 reactions, 564, 565 dimethylarsinoyl, 415 Abietadiene, 505, 506 oxocarboxylic, 550 Abietic acid, 189 phenolic, 551 Absinthin, 634 reactions, 555 Acacetin, 695 sugar, 212 Acacipetalin, 775, 776 Acidulants, 872 Acenaphthene, 919 Aconitic acid, 546 Acenaphthylene, 919 Acorin, 635 Acephate, 1010 Acrolein, 82 Aceric acid, 213, 214, 259 reactions, 180, 181, 193, 527, 538 Acesulfame K, 865, 866, 870 Acromelic acids, 829 Acetaldehyde, 72, 527 Acrylamide, 899, 900 reactions, 295, 538, 540 content in foods, 900 Acetals, 537, 541 reactions, 901, 902 reactions, 538 Acrylic acid, 1034 Acetic acid, 542, 850 Acrylonitrile, 1039 reactions, 296, 297, 543 Actin, 47 Acetoacetic acid, 551 Actinin, 47 Acetoin, 522, 536 Acylchloropropanediols, 910 reactions, 522 Acyloins, 536 Acetol, see hydroxyacetone Acylsphingosines, see ceramides Acetone, 533 Additives, 847 reactions, 540 Adenine, 396, 397 Acetophenone, 535 Adenosine diphosphate, see ADP Acetylcholine, 399 monophosphate, see AMP Acetylcysteines, see mercapturates triphosphate, see ATP Acetylfuran, 286 Adenylic acid, see AMP Acetylgalactosamine, 53, 58 Adermine, see vitamin B6 Acetylglucosamine, 58 Adhesives, 889 Acetylhistidines, 20 Adhyperflorin, 712 Acetyllactaminic acid, see acetylneuraminic acid Adipic acid, 544 Acetyllysine, 18 ADP, 18, 874 Acetylmuramic acid, 217 Adrastin, 951 Acetylneuraminic acid, 53, 58, 217 COPYRIGHTEDAdrenaline, MATERIALsee epinephrine Acetylpyridine, 590 Adriatoxin, 838 Acetylpyrroline, 18, 501 Advanced glycation end products, 319–23 Acetylpyrroline, reactions, 599 lipoxidation end products, 319 Acetyltetrahydropyridine, 18 Aflatoxicol, 946 Acetyltetrahydropyridine, reactions, 600 Aflatoxins, 942, 945–8 Acids as preservatives, 848 Aflatrem, 961 lipoamino, 129 Afzelechins, 648 aldonic, 212 Agar, 269 alicyclic, 551 Agaric acid, see agaricinic acid aromatic, 551 Agaricinic acid, 835, 865 bile, 140 Agaricone, 705 The Chemistry of Food, First Edition.
    [Show full text]
  • Synthesis and Biological Evaluation of Sparsomycin Analogues
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 1981 Synthesis and biological evaluation of sparsomycin analogues Scherer Preston Sanders Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medicinal and Pharmaceutical Chemistry Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/5601 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. SYNTHESIS AND BIOLOGICAL EVALUATION OF SPARSOMYCIN ANALOGUES by Scherer Preston Sanders Duke B.S. , College of William and Mary , 1977 Thesis submitted in partial fulfillment of the requirements for the Degree of Doctor of Philosophy in the Department of Pharmaceutical Chemistry at the Medical College of Virginia, Virginia Commonwealth University Richmond , Virginia August , 1981 ii This thesis by Scherer Preston Sanders Duke is accepted in its present form as satisfying the thesis requirement for the degree of Doctor of Philosophy . Date : Approved: 1- l I � I · •.•..... ••... •..•.•...•• - TJl ':7 J. � · . •. [v:7. � !� t 9 r ! ..... /) · ....� . �J.) . (q.ft... · ... :r u.l'f . .�l t. I g 8-l........ · .. Cf4r,;2/., . 1'1.f1..... Approved : . Chairman , MCV Graduate Council; Dean , Schoo l of Basic Sciences iii Scherer Preston Sanders Duke 1981 All Rights Reserved iv ACKNOWLEDGMENTS I wish to thank the members of my graduate committee for overseeing this project and especially my advisor , Dr. Marvin R. Boots , for his guidance and encouragement throughout the course of this research and the preparation of this thesis.
    [Show full text]
  • Cell Cycle Phase Specificity of Antitumor Agentsl
    [CANCER RESEARCH 32, 398-407, February 1972] Cell Cycle Phase Specificity of Antitumor Agentsl B. K. Bhuyan, L. G. Scheldt, and T. J. Fraser Research Laboratories, The Upjohn Company, Kalamazoo, Michigan 49001 SUMMARY correlating the biochemical effect of the drug to its lethal effect. For example, many drugs are maximally toxic to cells The sensitivity to drugs of synchronous and asynchronous at the G]-S boundary, and a correlation between the lethal populations of DON cells was studied. Agents that were and biochemical effects of the drug may help to delineate the cytotoxic at a specific phase of the cell cycle gave dose-survival biochemical reaction that triggers the cell across the Gi-S curves that decreased to a constant saturation value. DNA boundary, (b) They may help in designing combinations of synthesis inhibitors such as 1-0-D-arabinofuranosylcytosine, drugs on a rational basis. Thus, 2 drugs affecting the same 5-azacytidine, 5-hydroxy-2-formylpyridinethiosemicarbazone phase of the cell cycle would not give additive effects, if (NSC 107392), sodium camptothecin (NSC 100880), combined. 5-fluorodeoxyuridine, and pseudourea (NSC 56054) were Our studies were intended to determine the phase most cytotoxic to cells in the S phase. However, the DNA specificity of several clinically active agents and of agents with synthesis inhibitor, neocarzinostatin, was most cytotoxic to known biochemical activity. Parts of this study were reported cells in the G! phase. The protein synthesis inhibitors, previously (7). pactamycin and sparsomycin, were also most cytotoxic to cells in the S phase. Cells in the Gi-S border region were most MATERIALS AND METHODS sensitive to the RNA synthesis inhibitors, actinomycin D and nogalamycin, and to the alkylating agents, Cell Culture.
    [Show full text]
  • The Ribosomal Peptidyl Transferase Center: Structure, Function, Evolution, Inhibition
    Critical Reviews in Biochemistry and Molecular Biology, 40:285–311, 2005 Copyright c Taylor & Francis Inc. ISSN: 1040-9238 print / 1549-7798 online DOI: 10.1080/10409230500326334 The Ribosomal Peptidyl Transferase Center: Structure, Function, Evolution, Inhibition Norbert Polacek Innsbruck Biocenter, Division of ABSTRACT The ribosomal peptidyl transferase center (PTC) resides in the Genomics and RNomics, large ribosomal subunit and catalyzes the two principal chemical reactions of Innsbruck Medical University, protein synthesis: peptide bond formation and peptide release. The catalytic Innsbruck, Austria mechanisms employed and their inhibition by antibiotics have been in the Alexander S. Mankin focus of molecular and structural biologists for decades. With the elucidation Center for Pharmaceutical of atomic structures of the large ribosomal subunit at the dawn of the new Biotechnology, University of millennium, these questions gained a new level of molecular significance. The Illinois at Chicago, Chicago, crystallographic structures compellingly confirmed that peptidyl transferase is IL 60607, USA an RNA enzyme. This places the ribosome on the list of naturally occurring riboyzmes that outlived the transition from the pre-biotic RNA World to con- temporary biology. Biochemical, genetic and structural evidence highlight the role of the ribosome as an entropic catalyst that accelerates peptide bond for- mation primarily by substrate positioning. At the same time, peptide release should more strongly depend on chemical catalysis likely involving an rRNA group of the PTC. The PTC is characterized by the most pronounced accu- For personal use only. mulation of universally conserved rRNA nucleotides in the entire ribosome. Thus, it came as a surprise that recent findings revealed an unexpected high level of variation in the mode of antibiotic binding to the PTC of ribosomes from different organisms.
    [Show full text]
  • Colloidal Dispersions
    0356 ch 021(293-318).ps 3/7/05 8:14 AM Page 293 CHAPTER 21 Colloidal Dispersions Bill J Bowman, PhD Clyde M Ofner III, PhD Hans Schott, PhD The British chemist Thomas Graham applied the term “colloid” An appreciable fraction of atoms, ions, or molecules of col- (derived from the Greek word for glue) ca 1850 to polypeptides loidal particles are located in the boundary layer between the such as albumin and gelatin; polysaccharides such as acacia, particle and the dispersion medium. The boundary layer be- starch, and dextrin; and inorganic compounds such as gelati- tween a particle and air is commonly referred to as a surface; nous metal hydroxides and Prussian blue (ferric ferrocyanide). whereas, the boundary layer between a particle and a liquid or Contemporary colloid and surface chemistry deals with an un- solid is commonly referred to as an interface. The ions/molecules usually wide variety of industrial and biological systems. A few within the particle and within the medium are surrounded on all examples include catalysts, lubricants, adhesives, latexes for side by similar ions/molecules and have balanced force fields; paints, rubbers and plastics, soaps and detergents, clays, ink, however, the ions/molecules at surfaces or interfaces are sub- packaging films, cigarette smoke, liquid crystals, drug delivery jected to unbalanced forces of attraction. Consequently, a surface systems, cell membranes, blood, mucous secretions, and aque- free energy component is added to the total free energy of col- ous humors.1–3 loidal particles and becomes important as the particles become smaller and a greater fraction of their atoms, ions, or molecules are located in the surface or interfacial region.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Sparsomycin Item No. 29934 CAS Registry No.: 1404-64-4 Formal Name: (2E)-N-[(1S)-1-(hydroxymethyl)-2-[(R)- [(methylthio)methyl]sulfinyl]ethyl]-3- (1,2,3,4-tetrahydro-6-methyl-2,4-dioxo- OH O 5-pyrimidinyl)-2-propenamide O O Synonyms: NSC 059729, NSC 59729, H S S (+)-Sparsomycin, U-19183 N N MF: C13H19N3O5S2 H FW: 361.4 O N Purity: ≥95% Supplied as: A solid H Storage: -20°C Stability: ≥2 years Item Origin: Bacterium/Streptomyces sp. Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Sparsomycin is supplied as a solid. A stock solution may be made by dissolving the sparsomycin in the solvent of choice, which should be purged with an inert gas. Sparsomycin is soluble in organic solvents such as ethanol, methanol, DMSO, and dimethyl formamide. Description Sparsomycin is a bacterial metabolite and a nucleoside analog of uracil that has been found in S. sparsogenes and has diverse biological activities.1-3 It is active against KB carcinoma cells, Gram-positive and Gram-negative bacteria, and fungi.4 Sparsomycin is an inhibitor of peptidyl transferase that interferes with tRNA binding to the A-site of the peptidyl transfer center and increases the binding of peptidyl-tRNA to the P-site.2 It inhibits protein synthesis in bacteria, archaea, and eukaryotes.2,3 Sparsomycin reduces tumor growth in a P388 mouse leukemia model and in a Walker 256 carcinosarcoma rat model.5 References 1. Ottenheijm, H.C., van den Broek, L.A., Ballesta, J.P., et al.
    [Show full text]
  • Sparsomicin \Sc-Rs\ Compounds Having Antitumor Activity, a Process for Their Preparation and Pharmaceutical Compositions Contain
    Europaisches Patentamt J European Patent Office GO Publication number: 0 324 993 Office europeen des brevets A1 EUROPEAN PATENT APPLICATION © Application number: 88200109.2 © int. ci.-h C07D 239/54 , C07D 403/06 , A61K 31/505 © Date of filing: 21.01.88 @ Date of publication of application: © Applicant: Stichting Katholieke Universiteit 26.07.89 Bulletin 89/30 Toernooiveld 1 NL-6525 ED Nijmegen(NL) © Designated Contracting States: AT BE CH DE ES FR GB GR IT LI LU NL SE @ Inventor: Ottenheijm, Henricus Carl Joseph Gagelveid 5 NL-6595 CC Milsbeek(NL) © Representative: Smulders, Theodorus A.H.J., Ir. et ai Vereenigde Octrooibureaux Nieuwe Parklaan 107 NL-2587 BP 's-Gravenhage(NL) © Sparsomicin (Sc-Rs) compounds having antitumor activity, a process for their preparation and pharmaceutical compositions containing sparsomycin (Sc-Rs) compounds. © The invention relates to novel sparsomycin (Sc-Rs) compounds having valuable antitumor activity, and to a process for their preparation and pharmaceutical compositions containing such novel compounds. The novel compounds satisfy the general formula CO CO a. LU Xerox Copy Centre EP 0 324 993 A1 Sparsomycin (S0-Rs) compounds having antitumor activity, a process for their preparation and pharmaceutical compositions containing sparsomycin (Sc-Rs) compounds The invention relates to novel sparsomycin (Sc-Rs) compounds having valuable pharmacological properties, in particular a strong antitumor activity, a relatively low toxicity, a good solubility in aqueous media and a potentiating effect on the cytostatic activity of other cytostatics, such as, for example, cis- platinum and 5-fluorouracil. The invention also relates to pharmaceutical compositions containing such novel sparsomycin (S0-Rs) compounds, and to a process for preparing said novel sparsomycin (S0-Rs) compounds.
    [Show full text]
  • Biochemical Studies on the Production of Sparsomycin Antibiotic by Pseudomonas Aeurginosa, AZ-SH-B8 Using Plastic Wastes As Fermented Substrate
    Journal of Saudi Chemical Society (2012) 16, 35–44 King Saud University Journal of Saudi Chemical Society www.ksu.edu.sa www.sciencedirect.com ORGINAL ARTICLE Biochemical studies on the production of Sparsomycin antibiotic by Pseudomonas aeurginosa, AZ-SH-B8 using plastic wastes as fermented substrate Houssam M. Atta *, Hassan G. Radwan Botany and Microbiology Dept., Faculty of Science (Boys), Al-Azhar University, Cairo, Egypt Received 3 October 2010; accepted 24 October 2010 Available online 3 November 2010 KEYWORDS Abstract Hundred and twenty microbial isolates could be isolated from different soil samples col- Biochemical studies; lected from different localities in Egypt. One of the bacterial cultures AZ-SH-B8 was found to pro- Pseudomonas aeurginosa; duce a wide spectrum antimicrobial agent when cultivated on plastic wastes. The bacterial culture Parameters; AZ-SH-B8 could be isolated from a soil sample collected from Sharkia governorate, Egypt. From Production of antimicrobial the taxonomic features, the bacterial isolate AZ-SH-B8 matches with Pseudomonas aeurginosa in agent; the morphological, physiological and biochemical characters and confirmation by using API20E Sparsomycin antibiotic system. Thus, it was given the suggested name P. aeurginosa, AZ-SH-B8. The parameters control- ling the biosynthetic process of antimicrobial agent formation includes: innoculum size, different pH values, different temperatures, different incubation period, different carbon and nitrogen sources and different mineral salts concentrations (KNO3,K2HPO4, MgSO4Æ7H2O and KCl) were fully investigated. The active metabolite was extracted using n-butanol (1:1, v/v) at pH 7.0. The sep- aration of the active ingredient and its purification was performed using both thin layer chromatog- raphy (TLC) and column chromatography (CC) techniques.
    [Show full text]